A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

NCT07232719 · tracked via the Priya Life Science UK tracker

Sponsor

Eli Lilly and Company

Phase

Phase 3

Started

2025-11-17

Last updated

2026-04-17

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

RetatrutidePlacebo

Retatrutide: Administered SC

Placebo: Administered SC

Study summary

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.

Participation in the study will last about 65 weeks and may include about 18 visits.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Have a body mass index (BMI) of: * ≥30 kilogram per square meter (kg/m2) OR * ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease * Have at least one unsuccessful attempt to lose weight by dieting Exclusion Criteria: * Have a self-reported change in body weight \>5 kg (11 pounds) within 90 days before screening * Have a prior or planned surgical treatment for obesity * Have type 1 diabetes or type 2 diabetes * Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * Have had within the past 90 days before screening * acute myocardial infarction * cerebrovascular accident (stroke) * hospitalization for unstable angina, or * hospitalization due to congestive heart failure * Have New York Heart Association Functional Classification Class IV congestive heart failure * Have a history of chronic or acute pancreatitis * Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Primary outcome measure(s)

Percent Change from Baseline in Body Weight — Baseline, Week 56

Trial sites (31)

Facility	City	Region
Artemis Institute for Clinical Research	Riverside	California
JEM Research Institute	Atlantis	Florida
Headlands Research Orlando	Orlando	Florida
Care Access - Tamarac	Tamarac	Florida
Care Access - Arlington Heights	Arlington Heights	Illinois
L-MARC Research Center	Louisville	Kentucky
IMA Clinical Research Monroe - Armand	Monroe	Louisiana
Pharmasite Research, Inc.	Baltimore	Maryland
Clinical Research Professionals	Chesterfield	Missouri
Clinvest Headlands Llc	Springfield	Missouri
IMA Clinical Research Warren	Warren Township	New Jersey
IMA Clinical Research Manhattan	New York	New York
Trial Management Associates - Wilmington - Floral Parkway	Wilmington	North Carolina
Cedar Health Research	Dallas	Texas
Headlands Research-El Paso	El Paso	Texas
Cedar Health Research - Euless	Euless	Texas
Cedar Health Research - Fort Worth	Fort Worth	Texas
Care Access - Houston	Houston	Texas
IMA Clinical Research San Antonio	San Antonio	Texas
FutureMeds - Birmingham	Birmingham	United Kingdom
Layton Medical Centre	Blackpool	United Kingdom
Bradford on Avon Health Centre	Bradford on Avon	United Kingdom
FutureMeds - Liverpool	Bromborough	United Kingdom
Cheadle Community Hospital	Cheadle	United Kingdom
HMC Health Group - Meadows Centre for Health	Hounslow	United Kingdom
St Bartholomew's Medical Centre	Oxford	United Kingdom
Atlantic Medical	Penzance	United Kingdom
The Adam Practice	Poole	United Kingdom
Woodstock Bower Surgery	Rotherham	United Kingdom
Rame Group Practice	Torpoint	United Kingdom
Albany House Medical Centre	Wellingborough	United Kingdom

More Eli Lilly and Company trials in the UK

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Starting soon

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk Recruiting

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Active, not recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia Recruiting

Other trials for the same condition

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity Active, not recruiting

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight Active, not recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity Recruiting

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Active, not recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07232719 on ClinicalTrials.gov ↗ ← All trials in the UK